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NID = non-inflammatory diseases of the joints; RA = rheumatoid arthritis; RAGE = receptor for advanced glycation endproducts; sRAGE = soluble
RAGE.
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Abstract
The receptor for advanced glycation endproducts (RAGE)
interacts with distinct ligand families linked to the inflammatory
response. Studies in animal models suggest that RAGE is
upregulated in the inflamed joint and that blockade of the receptor,
using a ligand decoy soluble form of RAGE (sRAGE), attenuates
joint inflammation and expression of inflammatory and tissue-
destructive mediators. In this issue of Arthritis Research & Therapy,
Rille Pullerits and colleagues reported that plasma levels of sRAGE
were reduced in subjects with rheumatoid arthritis compared with
healthy controls or subjects with non-inflammatory joint disease.
These findings suggest the possibility that levels of sRAGE might
be a biomarker of inflammation. Not resolved by these studies,
however, is the intriguing possibility that endogenously higher
levels of sRAGE might be linked to a lower incidence of arthritis or
to the extent of inflammation. Nevertheless, although ‘cause or
effect’ relationships may not be established in this report,
fascinating insights into RAGE, inflammation and human arthritis
emerge from these studies.
Introduction
In this issue of Arthritis Research & Therapy, Pullerits and
colleagues [1] reported that plasma levels of soluble receptor
for advanced glycation endproducts (sRAGE) were
decreased in human subjects with rheumatoid arthritis (RA)
compared to healthy normal subjects or subjects with non-
inflammatory diseases of the joints (NID). Although no
significant differences were observed between levels of
synovial sRAGE in subjects with RA and NID, synovial
sRAGE levels significantly distinguished those RA subjects
treated with disease-modifying anti-rheumatic drugs
(DMARDs) from those not on these treatments. Subjects with
RA receiving methotrexate displayed significantly higher
levels of synovial sRAGE [1]. These fascinating findings,
based on a single observation point in each subject, prompt
us to consider whether sRAGE’s role is cause and/or effect
in disease/disease activity in the RA joint.
In this context, full interpretation of these findings will require
comprehensive answers to the questions such as the
following: Do plasma sRAGE levels vary from day to day in a
subject? Do they vary over the lifespan of the individual?
What were the levels of sRAGE in the RA subjects before the
onset of disease manifestation? What other environmental or
genetic factors might influence levels of sRAGE in the
individual subject? Despite these caveats, a key lesson in
these studies is that levels of sRAGE, at least in the synovial
fluid, might be modified by intense anti-inflammatory therapy.
Indeed, an emerging theme in the biology of RAGE links this
receptor to proinflammatory mechanisms. At least four
classes of inflammatory ligands, namely S100/calgranulins,
amphoterin (also known as high mobility group box I or
HMGB1), Mac-1, and advanced glycation endproducts
(AGEs), are signal transduction ligands of RAGE [2-5].
Intriguingly, these ligand families are upregulated in the
serum, the synovium or the fluid bathing the arthritic joint. In
certain cases, levels of S100/calgranulins and amphoterin,
for example, reflect the extent of disease activity [6-9]. Such
findings still do not resolve a key issue: is the modulation of
plasma sRAGE levels cause or effect? In this context, studies
in animal models have provided insights into mechanisms by
which RAGE might be linked to proinflammatory mechanisms.
RAGE, inflammation and arthritis: insights
from animal models
Experimental findings support the premise that the biology of
RAGE extends beyond diabetes [10]. For example, studies in
euglycemic mouse models of delayed-type hypersensitivity
and colitis in interleukin-10-null mice suggested that a
blockade of RAGE attenuated inflammation and the
upregulation of cytokines and transcription factors such as
NF-κB [2]. In the specific context of arthritis, administration of
soluble RAGE to mice with collagen-induced arthritis
attenuated clinical scores of joint inflammation, in parallel with
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decreased joint expression of cytokines and antigen/activity
of matrix metalloproteinases [11]. In other studies, evidence
strongly supporting roles for RAGE ligands in the develop-
ment of collagen-induced arthritis in mice was demonstrated
by a reduced arthritis score and the histological severity of
arthritis in animals treated with polyclonal antibodies against
amphoterin (HMGB1) [12].
These experiments strongly suggested that augmenting levels
of sRAGE was beneficial. Indeed, in the human model,
administration of methotrexate resulted in significantly
enhanced levels of soluble RAGE in synovial fluid, with a
trend toward increased levels in plasma [1]. Presumably, in
those subjects, levels of sRAGE rose in parallel with decreased
inflammation. It remains unclear whether methotrexate-
induced suppression of inflammation facilitated the generation/
stability of endogenous sRAGE and, thus, ligand-trapping
and reduced inflammation. Alternatively, did inflammation
ensue directly as a consequence of endogenously low
sRAGE levels – levels that were somehow modulated by
administration of methotrexate? Clearly, long-term prospec-
tive studies of measurement of plasma/synovial sRAGE in RA
subjects are needed. Is it possible that patterns of sRAGE
expression might help to identify subjects in whom
aggressive therapy may be indicated [13]?
These intriguing studies have striking parallels in the work of
Falcone and colleagues [14]. These investigators studied non-
diabetic men with or without coronary artery disease. They
found that the lowest levels of plasma sRAGE in these subjects
correlated with the highest incidence of coronary artery
disease. These studies, as in those of Pullerits and colleagues,
suggest that endogenously low levels of sRAGE might be
either a biomarker of inflammation and/or part of the problem.
How may this be settled? An important piece of this puzzle is
solved when the cellular source(s) of sRAGE are delineated.
What are the source(s) of plasma and
synovial sRAGE?
RAGE is expressed by multiple cell types, including vascular
and inflammatory cells – the latter including neutrophils,
mononuclear phagocytes and lymphocytes – and by synovial
cells [11]. The studies reported by Pullerits and colleagues
do not delineate the cellular sources of sRAGE measured in
the plasma and synovial fluid. In addition, the specific
mechanism by which sRAGE is generated remains unclear.
Further, does the species recognized by the commercially
available polyclonal and monoclonal antibodies employed by
Pullerits and colleagues reflect soluble RAGE perhaps
cleaved from the cell surface receptor? Alternatively, does
this assay recognize novel soluble splice variants of the
receptor [15-17]? The antibodies against RAGE employed in
the ELISA used by Pullerits and colleagues do not distinguish
between these two possible sources. Future studies must
investigate precisely which sources and species of sRAGE
are relevant to inflammatory arthritis.
Genetic variants, RAGE and RA
Previous studies suggested interesting links between RAGE
and human arthritis [11,18]. It has previously been shown that
a polymorphism of the gene encoding RAGE located within
the V-type immunoglobulin domain of RAGE, which results in
a glycine to serine substitution at amino acid position 82, is in
linkage disequilibrium with HLA-DR4 [18]. It was therefore
not surprising that the Ser82 allele was increased in RA
subjects [11]; what remains to be studied is whether the
variant is associated with disease activity. In that context, the
V-type immunoglobulin domain of RAGE is the site of ligand
binding. Thus, not surprisingly, studies in cell culture models
suggested that the protein product of the Ser82 isoform
displayed increased affinity for RAGE ligands versus that
observed with the wild type (Gly82) form [11]. It also remains
to be determined whether these variants relate to the
regulation of sRAGE in plasma or synovial fluid.
Perspectives
The work of Pullerits and colleagues adds to the growing
body of human data on RAGE, sRAGE, genetic variants and
inflammation. These investigators placed sRAGE for the first
time in synovial fluid and indicate that its levels might be
modulated by intense anti-inflammatory therapy. Although
‘cause or effect’ may not be elucidated from these
experiments, prospective studies in RA and other
inflammatory disorders should be undertaken to delineate
whether sRAGE levels are a reproducible and predictive
biomarker for the extent of inflammatory arthritis and/or the
response to disease-modifying/anti-inflammatory therapy.
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